Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 16/20 | 0.52 |
| ▸ | KCNH2 | Q12809 | 14/20 | 0.52 |
| ▸ | BACE2 | Q9Y5Z0 | 3/20 | 0.34 |
| ▸ | CTSD | P07339 | 1/20 | 0.33 |
| ▸ | SYK | P43405 | 1/20 | 0.33 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.32 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.32 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3239035 | 0.87 | BACE1 (0.52) | BACE1KCNH2BACE2SYKKCNQ2 | |
| SCHEMBL3359098 | 0.85 | BACE1 (0.39) | BACE1KCNH2BACE2CTSD | |
| SCHEMBL3249126 | 0.84 | BACE1 (0.50) | BACE1KCNH2BACE2CTSDSYK | |
| SCHEMBL3360703 | 0.84 | BACE1 (0.46) | BACE1KCNH2KCNQ2PDK2 | |
| SCHEMBL3777038 | 0.84 | BACE1 (0.46) | BACE1KCNH2BACE2CTSD | |
| SCHEMBL2496387 | 0.84 | BACE1 (0.71) | BACE1KCNH2BACE2 | |
| SCHEMBL3359264 | 0.83 | BACE1 (0.67) | BACE1KCNH2BACE2CTSD | |
| SCHEMBL3358437 | 0.83 | BACE1 (0.59) | BACE1KCNH2BACE2 | |
| SCHEMBL3359274 | 0.83 | BACE1 (0.77) | BACE1KCNH2BACE2 | |
| SCHEMBL3358459 | 0.82 | BACE1 (0.44) | BACE1KCNH2BACE2CTSD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2010056194-A1 | 5H-PYRROLO [ 3, 4-B] PYRIDIN DERIVATIVES AND THEIR USE | ASTRAZENECA AB (SE) | 2010-05-20 | — | — | WO | disclosed |
| WO-2010056194-A1 | 5H-PYRROLO [ 3, 4-B] PYRIDIN DERIVATIVES AND THEIR USE | ASTRAZENECA AB (SE) | 2010-05-20 | — | — | WO | disclosed |
| US-20100125081-A1 | NEW COMPOUNDS 574 | ASTRAZENECA AB (SE) | 2010-05-20 | — | — | US | disclosed |
| US-20100125081-A1 | NEW COMPOUNDS 574 | ASTRAZENECA AB (SE) | 2010-05-20 | — | — | US | disclosed |
| US-20100125081-A1 | NEW COMPOUNDS 574 | ASTRAZENECA AB (SE) | 2010-05-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100125081-A1 | NEW COMPOUNDS 574 | PSEN1, PSEN2, BACE1 | BACE1 3/4885KCNH2 4727/4885BACE2 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.